Nothing was said about p21 when I asked whether or not the trial was going as expected in relation to the preclinicals. The p21 tests hadn't been done yet for the higher doses.
In Reply to 'frrol'
I've voiced the same opinion on Kevetrin and some people here have pointed to management's statements that recent Phase 1 results are going as expected, e.g. with respect to P21 correlation. I don't know how this is really known unless management is privvy to early test results. That seems strange to me but I choose to believe them.
As for Brilacidin, I don't think announcement of the Phase 3 would itself would move the stock, but theconditions of the Phase 3 may be a catalyst, e.g. fast track approval.
Market Data 
Markets 
AI
